These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial. Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651 [TBL] [Abstract][Full Text] [Related]
3. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Michaud L; Bantilan K; Mauguen A; Moskowitz CH; Zelenetz AD; Schöder H J Nucl Med; 2023 Apr; 64(4):536-541. PubMed ID: 36549918 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875 [TBL] [Abstract][Full Text] [Related]
6. Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: A SAKK 38/07 trial post-hoc analysis. Ceriani L; Milan L; Cascione L; Gritti G; Dalmasso F; Esposito F; Pirosa MC; Schär S; Bruno A; Dirnhofer S; Giovanella L; Hayoz S; Mamot C; Rambaldi A; Chauvie S; Zucca E Hematol Oncol; 2022 Feb; 40(1):11-21. PubMed ID: 34714558 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma. Song MK; Chung JS; Shin HJ; Moon JH; Lee JO; Lee HS; Lee SM; Lee GW; Lee SE; Kim SJ Cancer Sci; 2012 Mar; 103(3):477-82. PubMed ID: 22126515 [TBL] [Abstract][Full Text] [Related]
8. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era. Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL. Zhao P; Yu T; Pan Z Ann Nucl Med; 2021 Jan; 35(1):24-30. PubMed ID: 33001389 [TBL] [Abstract][Full Text] [Related]
10. Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study. Genta S; Ghilardi G; Cascione L; Juskevicius D; Tzankov A; Schär S; Milan L; Pirosa MC; Esposito F; Ruberto T; Giovanella L; Hayoz S; Mamot C; Dirnhofer S; Zucca E; Ceriani L Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205765 [TBL] [Abstract][Full Text] [Related]
11. Burggraaff CN; Eertink JJ; Lugtenburg PJ; Hoekstra OS; Arens AIJ; de Keizer B; Heymans MW; van der Holt B; Wiegers SE; Pieplenbosch S; Boellaard R; de Vet HCW; Zijlstra JM; J Nucl Med; 2022 Jul; 63(7):1001-1007. PubMed ID: 34675112 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Song MK; Chung JS; Shin HJ; Lee SM; Lee SE; Lee HS; Lee GW; Kim SJ; Lee SM; Chung DS Ann Hematol; 2012 May; 91(5):697-703. PubMed ID: 22071570 [TBL] [Abstract][Full Text] [Related]
14. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729 [TBL] [Abstract][Full Text] [Related]
15. Baseline PET as prognostic index in diffuse large B-cell lymphoma and grade IIIb follicular lymphoma: a retrospective study of a single-center experience. Campiotti L; DE Palma D; Guasti L; Proserpio I; Casagrande S; Schiorlin I; Bolzacchini E; Suter M; Ogliari F; Squizzato A Q J Nucl Med Mol Imaging; 2021 Mar; 65(1):59-63. PubMed ID: 30781938 [TBL] [Abstract][Full Text] [Related]
16. Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation. Strüßmann T; Fritsch K; Baumgarten A; Fietz T; Engelhardt M; Mertelsmann R; Ihorst G; Duyster J; Finke J; Marks R Br J Haematol; 2017 Sep; 178(6):927-935. PubMed ID: 28643323 [TBL] [Abstract][Full Text] [Related]
17. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734 [TBL] [Abstract][Full Text] [Related]
18. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial. Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542 [TBL] [Abstract][Full Text] [Related]
19. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study. Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the prognostic value of different methods of calculating the tumour metabolic volume with Guzmán Ortiz S; Mucientes Rasilla J; Vargas Núñez JA; Royuela A; Navarro Matilla B; Mitjavila Casanovas M Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):340-346. PubMed ID: 32646783 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]